RESEARCH ARTICLE

Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer

Hye rim Ha1, Do-Youn Oh1,2*, Tae-Yong Kim1,2, KyoungBun Lee3, Kyubo Kim4, Kyung-Hun Lee1,2, Sae-Won Han1,2, Eui Kyu Chie4, Jin-Young Jang5, Seock-Ah Im1,2, Tae-You Kim1,2, Sun-Whe Kim5, Yung-Jue Bang1,2

1 Department of Internal medicine, Seoul National University Hospital, Seoul, South Korea, 2 Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea, 3 Department of Pathology, Seoul National University Hospital, Seoul, South Korea, 4 Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea, 5 Department of Surgery, Seoul National University Hospital, Seoul, South Korea

* ohdoyoun@anu.ac.kr

Abstract

Background

Ampulla of Vater cancer (AoV Ca) is a rare tumor, and its adjuvant treatment has not been established. The purpose of this study was to find out prognostic factors including host immunity and role of adjuvant treatment in AoV Ca.

Methods and Findings

We reviewed 227 AoV Ca patients with curative resection. Clinical characteristics, adjuvant treatment, disease-free survival (DFS) and overall survival (OS) were analyzed. Among all patients, 63.9, 36.1 and 33.9% had T1/T2, T3/T4 stage and lymph node-positive disease (LN+), respectively. OS of all patients was 90.9 months (95% CI: 52.9–129.0). OS was different according to neutrophil-to-lymphocyte ratio (HR 1.651, 95% CI: 1.11–2.47), platelet-to-lymphocyte ratio (HR 1.488, 95% CI: 1.00–2.21) and systemic inflammatory index (HR 1.669, 95% CI: 1.13–2.47). In multivariate analysis, adverse prognostic factors for OS included vascular invasion (HR 2.571, 95% CI: 1.20–5.53) and elevated CA 19–9 (HR 1.794, 95% CI: 1.07–3.05). A total of 104 patients (46.3%) received adjuvant treatment (25 out of 111 of T1/T2 & LN (-), 79 out of 116 of T3/T4 or LN (+)). In T3/T4 or LN (+) stage, adjuvant CCRT with maintenance chemotherapy provided the longest OS (5-year OS rate: 47.0 vs. 41.4%).

Conclusions

Vascular invasion and elevated CA 19–9 were adverse prognostic factors in resected AoV Ca. In T3/T4 or LN (+) stage, adjuvant CCRT with maintenance chemotherapy provided the best survival outcome. Adjuvant treatment should be further defined in AoV Ca, especially with poor prognostic factors.

OPEN ACCESS

Citation: Ha Hr, Oh D-Y, Kim T-Y, Lee K, Kim K, Lee K-H, et al. (2016) Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. PLoS ONE 11(3): e0151406. doi:10.1371/journal.pone.0151406

Editor: John Souglakos, University General Hospital of Heraklion and Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, GREECE

Received: August 17, 2015
Accepted: February 26, 2016
Published: March 14, 2016

Copyright: © 2016 Ha et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (Grant No. 1320090).

Competing Interests: The authors have declared that no competing interests exist.
Introduction

The annual incidence of biliary tract cancer (BTC) in the Western world is about 5–6 per 100,000, while the annual incidence in Korea is 10 per 100,000.[1, 2] BTC has a worse prognosis than other malignancies.[2] Surgical resection is the only treatment modality which offers a chance of cure.[3] Approximately 40 ~ 50% of cholangiocarcinoma and 30% of gallbladder cancer patients undergo surgery; however, even in those resected cases, many patients experience cancer recurrence.[4, 5] In 1999, there was a randomized controlled study to evaluate the role of adjuvant concurrent chemoradiotherapy (CCRT) in pancreatic and biliary cancers by The European Organization for Research and Treatment of Cancer, which failed to show survival gain.[6] Other retrospective studies of the role of radiotherapy after surgical resection showed better 5-year loco-regional disease-free survival (DFS) and overall survival (OS) rates, and several retrospective analyses also showed significantly better survival outcomes in lymph node-positive patients on adjuvant CCRT.[7–9]

Ampulla of Vater cancer (AoV Ca) accounts for 10–15% of BTC in Korea, which arises from distal to the confluence of the common bile duct with the main pancreatic duct.[10] Initial presentations of AoV Ca are usually related to biliary obstruction such as jaundice, red urine and pruritus, potentially resulting in early detection.[11] Approximately 80% of AoV Ca patients were detected at a potentially resectable stage at the time of diagnosis. [12] Prognosis of AoV Ca has been favorable compared with other biliary tract cancers originating from the intrahepatic or extrahepatic bile duct or gallbladder. However, resected patients relapse in many cases, which leads to an eventual 5-year survival rate of 20~50%. [7, 13] The identification of patients with poor prognosis after curative resection is important to improve survival outcomes. In parallel, the role of adjuvant treatment should be accurately defined in patients with poor prognosis. Because of the relatively low incidence of AoV Ca, a prospective study design is extremely difficult to answer those questions.

Several studies have reported on the prognostic factors of AoV Ca. Nowadays, host immunity and peritumoral inflammation are considered important factors in the carcinogenesis and prognosis of solid tumors. [14–17] However, in BTC, including AoV Ca, the prognostic role of host immunity and peritumoral inflammation has not been well documented.

In this study, we evaluated the prognostic factors to define the AoV Ca patients with poor prognosis after curative resection. In this analysis, we included immunity/inflammation markers. The other important purpose of this study was to determine the role of adjuvant treatment in AoV Ca.

Methods

Patients and data collection

This study was a retrospective analysis of de-identified patient-level data from medical charts. Patients who were diagnosed with AoV Ca and who underwent curative resection at the Seoul National University Hospital between 1997 and 2012 were enrolled. Diagnosis was confirmed by tissue pathology. Data of baseline demographics were collected, including gender, ECOG, stage, laboratory tests (total bilirubin, albumin, carcinoembryonic antigen (CEA), carbohydrate antigen 19–9 (CA 19–9), and neutrophil, platelet and lymphocyte counts). The data of adjuvant treatment patterns were also collected, including chemotherapy, radiotherapy and CCRT. Survival outcomes including disease-free survival (DFS) and overall survival (OS) were obtained as well.
Statistical analysis

Statistical analysis of categorical variables was performed using Pearson’s chi-square test or Fisher’s exact test, as appropriate. A t-test was used for comparison of means. Median DFS and OS for all patients were calculated using the Kaplan-Meier method and comparisons between groups were made using log-rank tests.

Neutrophil, lymphocyte and platelet count were obtained from preoperative laboratory tests. We calculated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as neutrophil and platelet counts divided by lymphocyte counts, respectively. We also used the systemic inflammatory index (SII) which was determined as neutrophil x platelet/lymphocyte.[18] The cut-off values for NLR, PLR and SII were obtained using receiver operating characteristic (ROC) curve analysis for predicting OS.

The impact of continuous numerical variables on clinical outcomes was evaluated using Cox regression. Multivariate analysis for DFS and OS was also performed using Cox regression models. Factors with $p<0.05$ in univariate analysis were examined in multivariate regression models. All statistical tests were two-sided, with significance defined as $p<0.05$.

Ethics

The study protocol was reviewed and approved by the Institutional Review Board of Seoul National University Hospital (H-1306-109-500). All studies were conducted according to guidelines for biomedical research (Declaration of Helsinki). Written informed consent was not given by participants but patients’ record and information was anonymized and de-identified prior to analysis.

Results

Patient characteristics

A total of 227 patients were included in this analysis (Table 1). Median age was 61.5 years old (range: 33.8–88.2), and there were 125 male patients (55.1%). With regard to T stage, T1/T2 was found in 63.9% of patients, and 77 patients (33.9%) had lymph node (LN) involvement. Stage I A/B and stage II A/B according to the American Joint Committee on Cancer Staging system, seventh edition, were shown in 58/53 and 38/73 patients, respectively. A total of 216 patients had adenocarcinoma on pathology review. Twenty-two patients (9.7%) had poorly differentiated histology. Mean (median, 95% CI) value of NLR was 2.32 (1.92, 0.39–20.50). Mean (median, 95% CI) value of PLR was 179.2 (158.8, 11.7–692.3). Mean (median, 95% CI) value of SII was 709.8 (544.8, 86.5–6478.0).

The follow-up duration of all patients was 48.0 months (95% CI: 43.5–52.4). Eighty-two patients experienced relapse and 105 patients were dead at the time of analysis. Median OS was 90.96 months (95% CI: 53.84–128.09), with 5-year OS rate of 58.3%. Median DFS was not reached and 5-year DFS rate was 62.5% (Fig 1).

The cut-off values of NLR, PLR and SII for predicting OS were 1.78, 192.0, and 780.0, respectively. The numbers of patients with NLR, PLR and SII values lower than cut-off were 100 (44.8%), 148 (65.2%) and 146 (64.3%), respectively (Table 1).

Prognostic factor and clinical outcomes

In univariate analysis, aged $<60$, CEA, CA-19-9, total bilirubin, NLR, PLR, SII and T/N stage were significant prognostic factors for 5-year OS (Table 2). Patients with lower NLR showed longer survival than patients with higher NLR (not achieved vs. 58.2 months, HR 1.651 (95% CI: 1.11–2.47), $p = 0.012$) (Fig 2A). In a similar way, lower PLR was associated with better
Table 1. Patient characteristics.

| Characteristic                      | Number | Percent (%) |
|-------------------------------------|--------|-------------|
| **Age**                             |        |             |
| Median(range)                       | 61.5 (33.8–88.2) |             |
| **Sex**                             |        |             |
| Male                                | 125    | 55.1        |
| Female                              | 102    | 44.9        |
| **T stage**                         |        |             |
| T1                                  | 68     | 30          |
| T2                                  | 77     | 33.9        |
| T3                                  | 77     | 33.9        |
| T4                                  | 5      | 2.2         |
| **N stage**                         |        |             |
| N0                                  | 150    | 66.1        |
| N1                                  | 77     | 33.9        |
| **Stage**                           |        |             |
| IA                                  | 58     | 25.6        |
| IB                                  | 53     | 23.3        |
| IIA                                 | 38     | 16.7        |
| IIB                                 | 73     | 32.2        |
| III                                 | 5      | 2.2         |
| **Pathology**                       |        |             |
| Adenocarcinoma                      | 216    | 95.2        |
| Adenosquamous                       | 2      | 0.9         |
| Mucinous                            | 3      | 1.3         |
| Neuroendocrine(Gr1,2/G3)            | 2/2    | 1.8         |
| Papillary                           | 2      | 0.9         |
| **Differentiation**                 |        |             |
| Well-differentated                  | 75     | 33.0        |
| Moderately-differentiated           | 124    | 54.6        |
| Poorly-differentiated               | 22     | 9.7         |
| Unknown                             | 6      | 2.6         |
| **Lymphatic invasion**              |        |             |
| No                                  | 120    | 52.9        |
| Yes                                 | 76     | 33.5        |
| Unknown                             | 31     | 13.7        |
| **Vascular invasion**               |        |             |
| No                                  | 177    | 78.0        |
| Yes                                 | 20     | 8.8         |
| Unknown                             | 30     | 13.2        |
| **Perineural invasion**             |        |             |
| No                                  | 156    | 68.7        |
| Yes                                 | 44     | 19.4        |
| Unknown                             | 27     | 11.9        |
| **Total bilirubin**                 |        |             |
| Normal                              | 110    | 48.5        |
| Elevated                            | 112    | 49.3        |
| Unknown                             | 5      | 2.2         |

(Continued)
survival (not achieved vs. 49.3 months, HR 1.767 (95% CI: 1.18–2.65), \( p = 0.043 \)) (Fig 2B). Patients with lower SII showed better survival (not achieved vs. 53.6 months, HR 1.669 (95% CI: 1.13–2.47), \( p = 0.010 \)) (Fig 2C). Patient characteristics according to NLR (low vs. high) were compared (Table 3). In the higher NLR group, a higher proportion of T3/4 stage, stage II/III, lymphatic/perineural invasion, high PLR, high SII was observed.

Regarding pathologic findings, degree of differentiation and lymphatic/vascular/perineural invasion were also significant prognostic factors for OS. On multivariate analysis, vascular invasion and elevated CA 19–9 were significant poor prognostic factors for 5-year OS (Table 2).

Adverse prognostic factors for 5-year DFS were differentiation, lymphatic/vascular/perineural invasion, CEA, CA 19–9, total bilirubin and T/N stage on univariate analysis. Differentiation and T/N stage showed significant differences for DFS on multivariate analysis (S1 Table).

### The patterns of adjuvant treatment

After curative resection of tumor, 104 patients (45.8%) received adjuvant treatment. Adjuvant treatment modalities according to tumor stage are shown in S2 Table.

A total 59 patients received adjuvant CCRT with maintenance chemotherapy, and 32 patients received adjuvant CCRT. Eight and five patients received adjuvant chemotherapy only and adjuvant radiotherapy only, respectively. The most commonly used chemotherapy was

---

**Table 1.** (Continued)

|                | Number | Percent (%) |
|----------------|--------|-------------|
| **Decreased**  | 42     | 18.5        |
| **Normal**     | 180    | 79.3        |
| **Unknown**    | 5      | 2.2         |
| **CEA**        |        |             |
| **Normal**     | 202    | 89.0        |
| **Elevated**   | 14     | 6.2         |
| **Unknown**    | 11     | 4.8         |
| **CA-19-9**    |        |             |
| **Normal**     | 142    | 62.6        |
| **Elevated**   | 76     | 33.5        |
| **Unknown**    | 9      | 4.0         |
| **NLR**        |        |             |
| \( \leq 1.78 \) | 100    | 44.8        |
| \( > 1.78 \)   | 123    | 54.2        |
| **Unknown**    | 4      | 1.8         |
| **PLR**        |        |             |
| \( \leq 192.0 \) | 148    | 65.2        |
| \( > 192.0 \)  | 75     | 33.0        |
| **Unknown**    | 4      | 1.8         |
| **SII**        |        |             |
| \( \leq 780.0 \) | 146    | 64.3        |
| \( > 780.0 \)  | 77     | 33.9        |
| **Unknown**    | 4      | 1.8         |

CEA, carcinoembryonic antigen; CA-19-9, carbohydrate antigen-19-9; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-neutrophil ratio; SII, systemic inflammatory index.

doi:10.1371/journal.pone.0151406.t001
5-FU based one. During CCRT, the regimen 5-FU 500 mg/m², D1,2,3 q 4 weeks was most commonly used, followed by 5-FU/leucovorin (375 mg/m², 20 mg/m², respectively, D1-5, q 4 weeks). During maintenance chemotherapy or adjuvant chemotherapy alone, 5-FU 500 mg/m², D1-5 q 4 weeks was most commonly used for 6 months. Radiotherapy was administered at a dose of 45 Gy in 25 fractions.

When we analyzed survival outcomes according to adjuvant treatment, there was no significant difference in stage 1A and 1B. However, in T3/T4 or LN (+) stage, the patients who received adjuvant CCRT with maintenance chemotherapy had better 5-year OS, even though the finding was not statistically significant (Table 4, Fig 3).

In patients who received adjuvant treatment, NLR, PLR and SII were all important factors for OS. However, this was not the case in patients without adjuvant treatment (Table A and B in S1 File).

**Discussion**

In this study, we found that in curatively resected AoV Ca, vascular invasion in pathologic examination and elevated CA 19–9 were poor prognostic factors. Patients who had T3/T4 or LN (+) tumors showed good survival when they received adjuvant CCRT with maintenance chemotherapy.

Tumor stage, lymph node involvement and vascular/perineural invasion were well-known prognostic factors in biliary tract cancer. [19] In our study, T/N stage, presence of lymphatic/
Table 2. Analysis of prognostic factor for OS.

| Factor               | 5Y- OS (%) | Univariate analysis | Multivariate analysis |
|----------------------|------------|---------------------|-----------------------|
|                      |            | HR(95% CI) | P       | HR(95% CI) | P       |
| **Age**              |            |            |         |            |         |
| < 60                 |            | 66.5       | 0.015   | 1.503      | 0.104   |
| ≥60                  |            | 52.3       |         |            |         |
| **Size**             |            |            |         |            |         |
| < 2 Cm               |            | 54.5       | 0.121   |            |         |
| ≥2 Cm                |            | 61.2       |         |            |         |
| **Pathology**        |            |            |         |            |         |
| Adenocarcinoma       |            | 58.7       |         |            |         |
| Adenosquamous        |            | 0.0        |         |            |         |
| Mucinous             |            | 66.7       |         |            |         |
| Neuroendocrine       |            | 75.0       |         |            |         |
| Papillary            |            | 0.0        |         |            |         |
| **Differentiation**  |            |            |         |            |         |
| Well-diff            |            | 76.7       |         |            |         |
| Mod-diff             |            | 53.9       |         |            |         |
| Poorly-diff          |            | 27.1       |         |            |         |
| **Lymphatic invasion** |        |            |         |            |         |
| No                   |            | 72.2       | 0.004   | 0.749      | 0.339   |
| Yes                  |            | 44.1       |         |            |         |
| **Vascular invasion** |          |            |         |            |         |
| No                   |            | 65.1       | 0.001   | 2.616      | 0.015   |
| Yes                  |            | 24.0       |         |            |         |
| **Perineural invasion** |       |            |         |            |         |
| No                   |            | 68.2       | 0.001   | 1.549      | 0.166   |
| Yes                  |            | 29.6       |         |            |         |
| **CEA**              |            |            |         |            |         |
| Normal               |            | 60.9       | 0.001   | 1.473      | 0.357   |
| Elevated             |            | 25.7       |         |            |         |
| **CA-19-9**          |            |            |         |            |         |
| Normal               |            | 67.7       | 0.001   | 1.787      | 0.030   |
| Elevated             |            | 43.1       |         |            |         |
| **Albumin**          |            |            |         |            |         |
| Decreased            |            | 41.0       | 0.057   |            |         |
| Normal               |            | 62.3       |         |            |         |
| **Total bilirubin**  |            |            |         |            |         |
| Normal               |            | 72.9       | 0.001   | 1.115      | 0.695   |
| Elevated             |            | 44.4       |         |            |         |
| **T stage**          |            |            |         |            |         |
| T1                   |            | 74.7       | 0.001   | 1.342      | 0.085   |
| T2                   |            | 66.1       |         |            |         |
| T3                   |            | 38.9       |         |            |         |
| T4                   |            | 0.0        |         |            |         |
| **N stage**          |            |            |         |            |         |
| N0                   |            | 69.7       | 0.001   | 1.617      | 0.086   |
| N1                   |            | 36.2       |         |            |         |
| **NLR**              |            |            |         |            |         |
|                      |            | 1.651      | 0.012   | 1.280      | 0.418   |

(Continued)
vascular/perineural invasion, histologic differentiation and elevated total bilirubin/CEA/CA 19–9 were adverse prognostic factors.

In cancer development and progression, the role of inflammation has been highlighted.[15–17, 20] As systemic inflammatory response is activated, neutrophils increase, and in parallel, lymphocytes decrease in peripheral blood. For several years, the index representing the systemic inflammatory state has been developed and several markers such as NLR, PLR and SII have been analyzed in various tumor conditions except AoV Ca.[21, 22] Tumor antigens elicit an adaptive immune response by inflammatory cells, macrophages and lymphocytes. CD4+ T cells and CD8+ T cells have important roles in this process, and especially tumor-infiltrating CD8+ T lymphocytes improve prognosis in several cancers.[23, 24] NLR, PLR and SII may represent these immune response processes and be of prognostic significance.[25, 26]

We analyzed the association of OS and host immunity and inflammation status such as NLR, PLR and SII. The patients with NLR \( \leq 1.78 \) or PLR \( \leq 192.0 \) or SII \( \leq 780.0 \) showed significantly prolonged OS. We selected the cut-off values of NLR, PLR and SII using ROC analysis for OS. NLR and PLR showed a linear relationship \( (r^2 = 0.82) \) and NLR and SII also showed a linear relationship \( (r^2 = 0.88) \). Patients with higher NLR included a higher proportion of T3/4 stage, stage II/III and lymphatic/perineural invasion compared with patients with lower NLR. To the best of our knowledge, this is the most extensive analysis in AoV Ca patients focused on host immunity and inflammation status.

The role of adjuvant treatment in BTC patient has not been established. An earlier retrospective analysis of survival outcomes in patients with adjuvant therapy showed that OS was improved insignificantly.[27] Recently, another study also reported that neoadjuvant and adjuvant chemotherapy did not provide survival benefit.[28] However, a meta-analysis reported survival benefit in patients with LN (+) or R1 resection by adjuvant therapy.[29] The study was reported that the patients with KRAS<sup>G12D</sup> mutation show poor prognoses and high risk of early recurrence, and adjuvant therapy will be effective in the high risk patients.[30] In these circumstances, according to National Comprehensive Cancer Network (NCCN) guidelines, adjuvant therapy is recommended for R1 or R2 resected or LN (+) patients. In case of R0 resection with no LN involvement or carcinoma in situ at resection margins, four options are all recommended, that is, observation or fluoropyrimidine-based chemoradiation or fluoropyrimidine-based or gemcitabine-based chemotherapy or clinical trial.

In our study, 25% of patients received adjuvant treatment in T1/T2 & LN (-) stage. The percentage of delivered adjuvant treatment was increased with stage, where nearly 70% of patients

Table 2. (Continued)

| 5Y- OS (%) | Univariate analysis | Multivariate analysis |
|------------|---------------------|----------------------|
|            | HR(95% CI)          | P        | HR(95% CI)          | P        |
|            | ≤1.78               | 1.78     | 68.3                | 49.4     |
|            | >1.78               | 1.78     | 68.3                | 49.4     |
| PLR        | ≤192.0              | 192.0    | 63.8                | 46.4     |
|            | >192.0              | 192.0    | 63.8                | 46.4     |
| SII        | ≤780                | 780      | 64.7                | 45.1     |
|            | >780                | 780      | 64.7                | 45.1     |

NA, not achieved; CEA, carcinoembryonic antigen; CA-19-9, carbohydrate antigen-19-9; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-neutrophil ratio; SII, systemic inflammatory index.

doi:10.1371/journal.pone.0151406.t002
with T3/T4 or LN (+) stage received adjuvant treatment. Because LN involvement is a well-known adverse prognostic factor, most patients with LN (+) or T3/T4 tumors received adjuvant treatment. CCRT followed by maintenance chemotherapy, mostly 5-FU-based, was the most commonly used adjuvant treatment modality in our study. These data gave us information on the adjuvant treatment regimens for AoV Ca. While adjuvant treatment did not provide survival benefit in T1/T2 stage patients, adjuvant CCRT with maintenance chemotherapy resulted in better survival in T3/T4 or LN-positive patients (no treatment vs. CCRT with maintenance chemotherapy; 41.4 vs. 47.0%, p = 0.182). Although it was not statistically significant, it suggested the potential benefit of CCRT with maintenance chemotherapy in this population. Adjuvant chemotherapy, adjuvant radiotherapy and adjuvant CCRT without maintenance chemotherapy did not have an impact on the survival of T3/T4 or LN (+) patients as well as those T1/T2 & LN (-).

One of the limitations of our study was the design, i.e., retrospective, single center study. The adjuvant treatment was not applied based on a consistent principle of guidelines, and

Fig 2. OS according to NLR (A), PLR (B) & SII(C). (A)(B) show OS according to NLR and PLR. High NLR and high PNR has poorer OS than low NLR, low PLR. (C) shows OS according to SII, high SII also poorer OS, also.

doi:10.1371/journal.pone.0151406.g002
Table 3. Comparison of patient characteristics according to NLR.

| Characteristic | NLR ≤ 1.78[N (%)] | NLR > 1.78[N (%)] | P value |
|---------------|------------------|------------------|--------|
| Age | 61.4(37.0–88.2) | 62.0(33.8–86.0) | 0.993 |
| Sex | | | |
| Male | 50(50.0) | 74(60.1) | 0.129 |
| Female | 50(50%) | 49(39.8) | |
| T stage | | | |
| T1 | 28(28.0) | 40(32.5) | 0.021 |
| T2 | 43(43.0) | 32(14.3) | |
| T3 | 29(29.0) | 47(38.2) | |
| T4 | 0(0.0) | 4(3.3) | |
| N stage | | | |
| N0 | 72(72.0) | 77(62.6) | 0.138 |
| N1 | 28(28.0) | 46(37.4) | |
| Stage | | | |
| IA | 25(25.0) | 33(26.8) | 0.048 |
| IB | 32(32.0) | 21(17.1) | |
| IIA | 15(15.0) | 23(18.7) | |
| IIB | 28(28.0) | 42(34.1) | |
| III | 0(0.0) | 4(3.3) | |
| Pathology | | | |
| Adenocarcinoma | 97(97.0) | 115(93.5) | 0.338 |
| Adenosquamous | 0(0.0) | 2(1.6) | |
| Mucinous | 2(2.0) | 1(0.8) | |
| Neuroendocrine | 1(1.0) | 3(2.4) | |
| Papillary | 0(0.0) | 2(1.6) | |
| Differentiation | | | |
| Well-differentiated | 35(35.3) | 38(31.9) | 0.392 |
| Moderately-differentiated | 57(57.6) | 66(55.5) | |
| Poorly-differentiated | 7(7.0) | 15(12.6) | |
| Lymphatic invasion | | | |
| No | 61(68.5) | 58(54.2) | 0.041 |
| Yes | 28(31.5) | 49(45.8) | |
| Vascular invasion | | | |
| No | 84(94.4) | 92(86.0) | 0.053 |
| Yes | 5(5.6) | 15(14.0) | |
| Perineural invasion | | | |
| No | 76(84.4) | 79(72.5) | 0.043 |
| Yes | 14(15.6) | 30(27.5) | |
| Total bilirubin | | | |
| Normal | 51(52.6) | 58(47.2) | 0.424 |
| Elevated | 46(47.4) | 65(52.8) | |
| Albumin | | | |
| Decreased | 16(52.6) | 26(21.1) | 0.384 |
| Normal | 81(83.5) | 97(78.9) | |
| CEA | | | |
| Normal | 92(96.8) | 109(91.6) | 0.110 |
| Elevated | 3(3.2) | 10(8.4) | |

(Continued)
therefore, the proportion of adjuvant treatment was different according to clinical factors such as stage. It was very difficult to see the genuine impact on prognosis of clinical factors and adjuvant treatment. Other limitation is relatively short follow-up duration, even though eighty-two patients experienced relapse and 105 patients were dead at the time of analysis. This relative short follow-up time might mask the survival difference that occurs later in the time course.

Nonetheless, our study has a value of providing information on adverse prognostic factors including host immunity and inflammation status and clinical outcomes of adjuvant treatment modalities in a relatively large AoV Ca cohort.

In conclusion, the AoV Ca patients with vascular invasion and elevated CA 19–9 showed poor prognosis after curative resection. Host immunity and inflammation status represented

| Table 3. (Continued) | NLR≤1.78[N (%)] | NLR>1.78[N (%)] | P value |
|----------------------|----------------|----------------|---------|
| CA-19-9              | Normal         | 68(72.3)       | 74(60.7) | 0.073   |
|                      | Elevated       | 26(27.7)       | 48(39.3) |         |
| PLR                  | ≤ 192.0        | 85(85.0)       | 63(51.2) | <0.001  |
|                      | > 192.0        | 15(15.0)       | 60(48.8) |         |
| SII                  | ≤ 780          | 95(95.0)       | 51(41.5) | <0.001  |
|                      | > 780          | 5(5.0)         | 72(58.5) |         |

CEA, carcinoembryonic antigen; CA-19-9, carbohydrate antigen-19-9; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-neutrophil ratio; SII, systemic inflammatory index.

| Table 4. Treatment outcomes by stage & adjuvant treatment. | 5-Y DFS (%) | Log-rank P | 5-Y OS (%) | Log-rank P |
|------------------------------------------------------------|-------------|------------|------------|------------|
| Total                                                      |             |            |            |            |
| CCRT + maintenance chemotherapy                           | 52.1        | 0.022      | 52.0       | 0.336      |
| CCRT                                                        | 45.4        |            | 46.5       |            |
| Chemotherapy                                               | 62.2        |            | 48.6       |            |
| Radiotherapy                                               | 60.0        |            | 26.7       |            |
| No treatment                                               | 72.9        |            | 66.0       |            |
| T1/T2 &LN(-)                                               |             |            |            |            |
| CCRT + maintenance chemotherapy                           | 75.0        | 0.165      | 77.8       | 0.699      |
| CCRT                                                        | 53.6        |            | 71.4       |            |
| Chemotherapy                                               | 75.0        |            | 55.6       |            |
| Radiotherapy                                               | 66.7        |            | 33.3       |            |
| No treatment                                               | 86.5        |            | 76.5       |            |
| T3/T4 or LN(+)                                             |             |            |            |            |
| CCRT + maintenance chemotherapy                           | 47.9        | 0.844      | 47.0       | 0.730      |
| CCRT                                                        | 43.1        |            | 41.3       |            |
| Chemotherapy                                               | 33.3        |            | 33.3       |            |
| Radiotherapy                                               | 50.0        |            | 0.0        |            |
| No treatment                                               | 43.5        |            | 41.4       |            |

CCRT; concurrent chemoradiotherapy, LN; lymph node, DFS; disease-free survival, OS; overall survival

doi:10.1371/journal.pone.0151406.t003
doi:10.1371/journal.pone.0151406.t004
by NLR, PLR or SII were also important for the prognosis. In T3/4 or LN-positive stage, patients who received adjuvant CCRT with maintenance chemotherapy showed favorable survival. Adjuvant treatment should be further defined in AoV Ca, especially with poor prognostic factors.

Supporting Information

S1 File. Analysis of prognostic factors for OS according to adjuvant treatment. (DOCX)

S1 Table. Analysis of prognostic factor for DFS. (DOCX)

S2 Table. The patterns of adjuvant treatment. (DOCX)

Acknowledgments

We thank the patients included in the current study.
Author Contributions
Conceived and designed the experiments: HRH DYO. Performed the experiments: HRH DYO TYK KHL SWH SAI TYK YJB KBL KBK EKC JYJ SWK. Analyzed the data: HRH DYO. Contributed reagents/materials/analysis tools: HRH DYO TYK KHL SWH SAI TYK YJB KBL KBK EKC JYJ SWK. Wrote the paper: HRH DYO.

References
1. Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, et al. Epidemiology of biliary tract cancers: an update. Annals of oncology. 2009; 20(1):146–59. doi: 10.1093/annonc/mdn533 PMID: 18667395
2. Jung K-W, Won Y-J, Hong K-J, Oh C-M, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer research and treatment: official journal of Korean Cancer Association. 2014; 46(9):109.
3. Riall TS, Cameron JL, Lillemoe KD, Winter JM, Campbell KA, Hruban RH, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6-to 10-year follow-up. Surgery. 2006; 140(5):764–72. PMID: 17084719
4. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Annals of surgery. 2007; 245(5):755. PMID: 17457168
5. Jang J-Y, Kim S-W, Do Joong Park YJA, Yoon Y-S, Choi MG, Suh K-S, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Annals of surgery. 2005; 241(1):77. PMID: 15621994
6. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Annals of surgery. 1999; 230(6):776. PMID: 10615932
7. Narang AK, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol. 2011; 28:126.
8. Zhou J, Hsu CC, Winter JM, Pawlik TM, Laheru D, Hughes MA, et al. Adjuvant chemoradiation and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Annals of surgery. 1999; 230(6):776. PMID: 10615932
9. Kim K, Chie EK, Jang J-Y, Kim SW, Oh D-Y, Im S-A, et al. Role of adjuvant chemoradiotherapy for ampulla of vater cancer. International Journal of Radiation Oncology*Biology*Physics. 2009; 75(2):436–41.
10. Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim Y-T, et al. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Annals of surgical oncology. 2007; 14(11):3195–201. PMID: 17710498
11. Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Annals of surgery. 1998; 228(1):87. PMID: 9671071
12. Sikora S, Balachandran P, Dimri K, Rastogi N, Kumar A, Saxena R, et al. Adjuvant chemo-radiotherapy in ampullary cancers. European Journal of Surgical Oncology (EJSO). 2005; 31(2):158–63.
13. Beger HG, Treitschke F, Gansauge F, Harada N, Hiki N, Mattfeldt T. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Archives of Surgery. 1999; 134(5):526–32. PMID: 10323425
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–74. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230
15. Chua W, Charles K, Baracos V, Clarke S. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British journal of cancer. 2011; 104(8):1288–95. doi: 10.1038/bjc.2011.106 PMID: 21448173
16. Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFIX chemotherapy. BMC cancer. 2013; 13(1):350.
17. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. International Journal of Cancer. 2014; 134(10):2403–13. doi: 10.1002/ijc.28536 PMID: 24122750
18. Hu B, Yang X-R, Xu Y, Sun Y-F, Sun C, Guo W, et al. Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research. 2014; 20(23):6212–22. doi: 10.1158/1078-0432.CCR-14-0442 PMID: 25271081

19. de Paiva Haddad LB, Patzina RA, Penteado S, Montagnini AL, da Cunha JEM, Machado MCC, et al. Lymph node involvement and not the histopathologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. Journal of Gastrointestinal Surgery. 2010; 14(4):719–28. doi:10.1007/s11605-010-1156-4 PMID: 20107918

20. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6):883–99. doi:10.1016/j.cell.2010.01.025 PMID: 20303878

21. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress A, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. British journal of cancer. 2013; 109(2):416–21. doi: 10.1038/bjc.2013.332 PMID: 23799847

22. Zhang Y, Peng Z, Chen M, Liu F, Huang J, Xu L, et al. Elevated neutrophil to lymphocyte ratio might predict poor prognosis for colorectal liver metastasis after percutaneous radiofrequency ablation. International Journal of Hyperthermia. 2012; 28(2):132–40. doi:10.3109/02656736.2011.654374 PMID: 22335227

23. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960–4. PMID: 17008531

24. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. Journal of Clinical Oncology. 2011; 29 (15):1949–55. doi: 10.1200/JCO.2010.30.5037 PMID: 21483002

25. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Fushiya N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. British journal of cancer. 2012; 107(6):988–93. doi: 10.1038/bjc.2012.354 PMID: 22878374

26. Perez DR, Baser RE, Cavnar MJ, Balachandran VP, Antonescu CR, Tap WD, et al. Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor. Annals of surgical oncology. 2013; 20(2):593–9. doi: 10.1245/s10434-012-2682-y PMID: 23054118

27. Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, et al. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. International Journal of Radiation Oncology*Biology*Physics. 2008; 70(3):735–43.

28. Jarnagin WR. Biliary tract: Is there a role for neoadjuvant and adjuvant therapy in biliary cancer? Nature Reviews Gastroenterology and Hepatology. 2012; 9(11):622–3. doi: 10.1038/nrgastro.2012.186 PMID: 23007479

29. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. Journal of Clinical Oncology. 2012; 30(16):1934–40. doi: 10.1200/JCO.2011.40.5381 PMID: 22529261

30. Valsangkar NP, Ingkakul T, Correa-Gallego C, Mino-Kenudson M, Masia R, Lillemoe KD, et al. Survival in ampullary cancer: Potential role of different KRAS mutations. Surgery. 2015; 157(2):260–8. doi: 10.1016/j.surg.2014.08.092 PMID: 25616942